These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Sequential alteration of peanut agglutinin binding-glycoprotein expression during progression of murine mammary neoplasia.
    Author: Rak JW, McEachern D, Miller FR.
    Journal: Br J Cancer; 1992 May; 65(5):641-8. PubMed ID: 1586590.
    Abstract:
    A sequential, quantitative loss of Peanut agglutinin (PNA) binding with progression of mouse mammary cells from normal to preneoplastic to neoplastic phenotypes was observed. Normal mammary epithelium, preneoplastic mammary lesions designated D2HAN (D2-type hyperplastic alveolar nodules) and a series of nine spontaneous tumours (D2ST1, D2ST2, D2ST3, D2ST4, D2A1, D2F2, D2.0R, D2.1, EMT6R08) derived from mice bearing D2HAN were grown in culture and analysed by flow cytometry with respect to PNA binding intensity to the cell surface. Primary cultures of normal mammary epithelium strongly bound PNA. A stepwise decrease in PNA binding by preneoplastic D2HAN cells and subsequent tumours arising from those hyperplastic lesions was observed. Three cloned tumour subpopulations derived from such tumours exhibited dramatic differences in PNA binding ranging from high (D2.0R) to low (D2.1) to very low (D2A1 cells). Their growth rate in vitro was similar. However, an inverse correlation between PNA binding and malignant characteristics, such as the incidence and latency of subcutaneous tumours and the efficiency of the tumour cells to form lung colonies after i.v. injection, existed. Cells subsequently derived from tumours resulting from injection of the D2.0R clone (high PNA binding, low tumorigenicity) were found to have diminished PNA binding properties and to be more tumorigenic when reimplanted into syngeneic mice. The difference in PNA binding (up to 50-fold) between normal mammary cells and other mouse mammary tumour cells, i.e., unrelated to D2HAN lesions, was also seen. These include six sister subpopulations derived from a single BALB/cfC3H mouse mammary tumour (lines: 67, 66c14, 168FARN, 4TO7, 68H, 64pT) as well as SP1 spontaneous CBA/J mouse mammary carcinoma. The difference was greatly reduced by neuraminidase treatment suggesting a masking of PNA binding sites by sialic acid. Separation of cell lysates by SDS-PAGE revealed a high molecular weight PNA binding glycoprotein (greater than 250 kd) expressed by normal mammary epithelium and preneoplastic D2HAN cells, but not by tumour cells regardless of neuraminidase treatment. A PNA reactive glycoprotein of approximately 90 kd was uniquely expressed in normal mammary epithelial lysates, although neuraminidase treatment exposed a similar band in a few tumour lines. Normal mammary epithelium, preneoplastic D2HAN cells, and the poorly tumorigenic clone D2.0R expressed a PNA binding glycoprotein of approximately 150 kd. This band appeared to be specifically sialylated during transition from the high PNA binding, low tumorigenic phenotype of D2.0R cells to the low PNA binding, highly tumorigenic phenotype of cells isolated from tumours resulting from s.c. implantation of D2.0R cells.(ABSTRACT TRUNCATED AT 400 WORDS)
    [Abstract] [Full Text] [Related] [New Search]